Bristol-Myers Squibb Co (LTS:0R1F)
$ 59.4 -0.61 (-1.02%) Market Cap: 119.70 Bil Enterprise Value: 163.01 Bil PE Ratio: 0 PB Ratio: 6.98 GF Score: 82/100

Bristol-Myers Squibb Co at Barclays Global Healthcare Conference Transcript

Mar 14, 2024 / 12:30PM GMT
Release Date Price: $53.05 (-1.94%)
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst

I'm pleased to welcome Bristol-Myers Squibb to the stage. My name is Carter Gould. I cover U.S. biopharma here. I'm pleased to welcome Lynelle Hoch, President, Cell Therapy Organization for Bristol; as well as Wendy Short Bartie, who runs the Hematology and Oncology business. Welcome both. Thank you very much for joining us today.

Unidentified Company Representative

Thank you, Carter.

Questions & Answers

Carter Lewis Gould;Lynelle B. Hoch
Barclays Bank PLC, Research Division - Senior Analyst;Bristol-Myers Squibb Company - President of Cell Therapy Organization

All right. Great. So obviously, we've got a big day tomorrow -- a big day today in terms of (inaudible) approval, but a big day tomorrow in terms of BCMA outcome. Briefing documents came out yesterday. Maybe Lynelle, just start with sort of your takeaways from the documents. Anything that surprised you and your level of confidence at this point?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot